

Supplementary Table 1. Baseline clinical characteristics of enrolled patients

Characteristics	All patients with DAS28 <2.6 at first year follow up (n=680)	Patients with DAS28 <2.6 and VAS-pain ≥4 (n=146)	Patients with DAS28 <2.6 and VAS-pain <4 (n=534)	p-value
Age (yr)	53.0±13.0	54.4±13.5	52.7±12.8	0.057
Female	553 (81.3)	121 (82.9)	432 (80.9)	0.587
Marital status, married	598 (87.9)	125 (85.6)	473 (88.6)	0.330
Smoking history				0.986
Ex-smoker	63 (9.3)	13 (8.9)	50 (9.3)	
Current smoker	42 (6.2)	9 (6.2)	33 (6.2)	
Never	575 (84.5)	124 (84.9)	451 (84.5)	
BMI (kg/m ²)	22.5±3.2	22.5±3.5	22.6±3.1	0.396
Disease duration (yr)	8.3±7.4	10.0±9.1	7.9±6.9	0.015
Tender joint count*	7.6±5.9	7.1±5.8	7.8±5.9	0.072
Swollen joint count*	6.1±5.0	5.8±5.3	6.2±4.9	0.197
ESR (mm/h)*	39.0 (23.0~56.0)	38.5 (23.3~49.8)	39.0 (23.0~57.0)	0.213
CRP (mg/dL)*	1.3 (0.5~2.8)	1.1 (0.5~2.6)	1.4 (0.5~2.9)	0.145
Rheumatoid factor (positivity) (n=657)	534/657 (81.3)	111/141 (78.7)	423/516 (82.0)	0.380
Anti-CCP antibody (positivity) (n=581)	479/581 (82.4)	103/125 (82.4)	376/456 (82.5)	0.988
Pain VAS*	6.0 (5.0~8.0)	7.0 (5.0~8.0)	6.0 (5.0~8.0)	<0.001
Physician's GA*	7.0 (5.0~8.0)	6.0 (5.0~8.0)	7.0 (5.0~8.0)	0.065
Patient's GA*	7.0 (6.0~8.0)	7.0 (6.0~9.0)	7.0 (6.0~8.0)	0.103
CDAI *	25.0 (20.0~31.0)	23.5 (18.0~30.8)	25.0 (20.0~31.0)	0.048
EQ-VAS (n=10)*	7.0 (4.5~8.0)	7.0 (5.0~7.5)	7.0 (5.0~8.0)	0.857
RAPID3*	15.3 (11.0~19.0)	12.8 (16.7~19.7)	15.0 (10.7~18.7)	0.001
Presence of hand erosions (n=583)	201/583 (34.5)	47/121 (38.8)	154/462 (33.3)	0.256
Presence of foot erosions (n=431)	150/431 (34.8)	43/89 (48.3)	107/342 (31.3)	0.003

Data are presented as number (%), mean±standard deviation, or median (interquartile range), unless otherwise indicated. DAS28: disease activity score of 28 joints, VAS: visual analog scale, BMI: body mass index, ESR: erythrocyte sedimentation rate, CRP: C-reactive protein, CCP: cyclic citrullinated peptide, GA: global assessment, CDAI: clinical disease activity index, EQ-VAS: EuroQol visual analog scale, RAPID3: routine assessment of patient index data 3. Continuous data were assessed by independent t-test, and categorical data were analyzed by chi-square test. *These data were assessed by Mann-Whitney U-test.

Supplementary Table 2. Baseline medication, extraarticular manifestations, and comorbidities of enrolled patients

Characteristics	All patients with DAS28 <2.6 at first year follow up (n=680)	Patients with DAS28 <2.6 and VAS-pain ≥4 (n=146)	Patients with DAS28 <2.6 and VAS-pain <4 (n=534)	p-value
Previous treatment				
Prior use of methotrexate	650 (95.6)	137 (93.8)	513 (96.1)	0.245
Prior use of biologic agents	159 (23.4)	45 (30.8)	114 (21.3)	0.017
Current treatment				
bDMARDs or tsDMARDs				0.001
Anti-TNF	270 (39.7)	53 (36.3)	217 (40.6)	
Rituximab	3 (0.4)	0 (0.0)	3 (0.6)	
Tocilizumab	294 (43.2)	82 (56.2)	212 (39.7)	
Abatacept	63 (22.5)	7 (4.8)	56 (10.5)	
JAKis	50 (7.4)	4 (2.7)	46 (8.6)	
Corticosteroid use	444 (65.3)	116 (79.5)	328 (61.4)	<0.001
Concomitant cDMARDs use	598 (87.9)	126 (86.3)	472 (88.4)	0.492
Comorbidities*				
Cardiovascular disorders	258 (37.9)	67 (45.9)	191 (35.8)	0.026
Neurological disorders	13 (1.9)	7 (4.8)	6 (1.1)	0.004
Pulmonary disorders	26 (3.8)	3 (2.1)	23 (4.3)	0.209
Endocrine disorders	243 (35.7)	62 (42.5)	181 (33.9)	0.055
Renal disorders	5 (0.7)	3 (2.1)	2 (0.4)	0.069
Gastrointestinal disorders	20 (2.9)	3 (2.1)	17 (3.2)	0.590
Viral/infectious disorders	28 (4.1)	7 (4.8)	21 (3.9)	0.642
Drug abuse/dependence	1 (0.1)	0 (0.0)	1 (0.2)	0.999
Mental illness	12 (1.8)	6 (4.1)	6 (1.1)	0.015
Hematology & Oncology	277 (40.7)	64 (43.8)	213 (39.9)	0.390

Data are presented as number (%). DAS28: disease activity score of 28 joints, VAS: visual analog scale, bDMARDs: biologic disease modifying anti-rheumatic drugs, tsDMARDs: targeted synthetic DMARDs, TNF: tumor necrosis factor, JAKis: janus kinase inhibitors, cDMARDs: conventional DMARDs. *These data were assessed by chi-square test or Fisher exact test due to low frequency.